Want to see SG:42T full AI Analyst Report?
Top Page
Trendlines Group
(SGX:42T)
Select Model
Select Model
Rating:47Neutral
Price Target:
S$0.06
▼(-30.00% Downside)
Action:Reiterated
Date:07/01/26
The score is weighed down primarily by weak financial performance—especially persistent negative operating/free cash flow and an unstable income profile (negative EBIT despite a profit swing). Technicals are neutral with the stock trading near key moving averages, providing limited support. Valuation contributes little because the negative P/E reduces comparability and no dividend yield is available.
Positive Factors
Balance-sheet strength
Low leverage and a sizable equity base give Trendlines durable financial resilience. This balance-sheet cushion supports ongoing funding of portfolio companies, reduces immediate solvency pressure and provides optionality to wait for value-realizing exits rather than forced disposals, improving strategic flexibility over the next several months.
Negative Factors
Negative operating and free cash flow
Persistent negative operating and free cash flow is a durable constraint: it forces reliance on existing equity, external funding or asset disposals to fund operations and portfolio support. Continued cash burn limits reinvestment capacity, raises funding and dilution risk, and can pressure the timing and quality of exit decisions over months ahead.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet strength
Low leverage and a sizable equity base give Trendlines durable financial resilience. This balance-sheet cushion supports ongoing funding of portfolio companies, reduces immediate solvency pressure and provides optionality to wait for value-realizing exits rather than forced disposals, improving strategic flexibility over the next several months.
Read all positive factors
Trendlines Group (42T) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$84.42M
Dividend YieldN/A
Average Volume (3M)9.96M
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth-27.86%
EPS GrowthN/A
CountrySG
Employees23
SectorFinancial
Sector Strength70
IndustryAsset Management
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,455,493,500
10 Day Avg. Volume4,639,890
30 Day Avg. Volume9,962,306
Financial Highlights & Ratios
PEG Ratio-0.30
Price to Book (P/B)0.85
Price to Sales (P/S)33.32
P/FCF Ratio-11.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Trendlines Group Business Overview & Revenue Model
Company Description
The Trendlines Group Ltd. is a private equity and venture capital firm focused on commercializing innovative technologies. They specialize in early-stage investments, ranging from incubation and seed funding to start-up and even later-stage ventur...
How the Company Makes Money
Trendlines Group generally makes money through a combination of (1) returns from its portfolio companies and (2) recurring/other income associated with operating its venture platform.
1) Portfolio company exits and value realization
- Equity appr...
Trendlines Group Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -8.32M | 1.99M | 1.72M | 4.50M | 3.58M | 2.30M |
| Gross Profit | -19.53M | 343.23K | -1.73M | -793.00K | -3.83M | -5.04M |
| EBITDA | -19.34M | 2.13M | -9.28M | -33.93M | -16.39M | 3.95M |
| Net Income | -18.87M | 1.95M | -9.43M | -33.99M | -14.48M | 6.56M |
Balance Sheet | ||||||
| Total Assets | 73.26M | 85.76M | 75.35M | 78.07M | 107.99M | 121.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.89M | 4.92M | 5.89M | 6.11M | 6.57M | 18.46M |
| Total Debt | 5.45M | 5.35M | 4.15M | 4.64M | 4.85M | 10.01M |
| Total Liabilities | 8.63M | 8.45M | 7.32M | 9.00M | 12.10M | 18.54M |
| Stockholders Equity | 65.47M | 78.26M | 68.55M | 70.89M | 96.99M | 103.09M |
Cash Flow | ||||||
| Free Cash Flow | -9.84M | -5.89M | -8.86M | -6.42M | -15.04M | 76.00K |
| Operating Cash Flow | -9.80M | -5.87M | -8.84M | -6.34M | -14.93M | 650.00K |
| Investing Cash Flow | -200.93K | -2.38M | -948.00K | 1.92M | 2.05M | -598.00K |
| Financing Cash Flow | 5.26M | 8.09M | 8.64M | 5.97M | 3.13M | 3.60M |
Trendlines Group Technical Analysis
Positive
0.08
Price Trends
0.06
Negative
0.06
Positive
0.06
Positive
Market Momentum
<0.01
Positive
53.53
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42T, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and above the 200-day MA of 0.06, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.53 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:42T.
Trendlines Group Peers Comparison
UnderperformOutperform
Sector (68)
SG:42T
Trendlines Group
0.06
0.03
110.71%
SG:5RF
Mercurius Capital Investment Limited
0.02
0.00
0.00%
SG:CJN
British and Malayan Holdings Limited
1.98
1.33
204.62%
SG:HKB
AMTD IDEA Group Class A
3.49
-0.11
-3.06%
SG:I49
IFS Capital Ltd.
0.18
0.05
42.28%
SG:YYN
Plato Capital Limited
3.05
0.03
0.99%
Trendlines Group Corporate Events
Trendlines taps related-party co-investment to bolster ProArc funding
Jul 1, 2026
Trendlines Group has approved a co-investment alongside related companies of controlling shareholder Librae Holdings in its portfolio company ProArc. The funding, structured as a Simple Agreement for Future Equity, will see both Trendlines and LH-...
Trendlines Updates Portfolio Milestones and Equity Incentive Moves
Jun 2, 2026
Trendlines Group reported a series of corporate developments, including new investments in portfolio companies Ceretrieve and Vensica Medical by entities related to Librae Holdings, underscoring continued backing for its medical technology pipelin...
Trendlines’ Phytolon Raises US$23.6 Million to Scale Natural Food Colors After FDA Nod
May 28, 2026
Trendlines portfolio company Phytolon has raised US$23.6 million in a three-stage Series B round, led by an undisclosed strategic investor, to accelerate commercialization of its fermentation-based natural food colors in the U.S. market. The finan...
Trendlines shareholders back board, auditors and tighter share-issue mandate at AGM
May 13, 2026
Trendlines Group held its annual general meeting in Singapore on 16 April 2026, where the board presented key business developments, the composition of its portfolio companies and financial highlights for fiscal 2025. The chair reaffirmed a commit...
Trendlines secures co-investments from controlling shareholder’s related entities for key portfolio firms
May 11, 2026
Trendlines Group has approved co-investments with entities related to its controlling shareholder Librae Holdings in two portfolio companies, Ceretrieve and Vensica Medical, totaling US$1.4 million, split between LH-related parties and Trendlines....
Trendlines-Backed Vensica Wins FDA Go-Ahead for Phase 2 Needle-Free Bladder Therapy
May 4, 2026
Vensica Medical, a clinical-stage urology company incubated by Trendlines Group, has received U.S. FDA clearance of its Investigational New Drug application to begin a Phase 2 trial of ViXe, a needle-free, ultrasound-based delivery system for Xeom...
Trendlines Highlights AGM Outcomes and Portfolio Breakthroughs in Food and Agri-Tech
Apr 30, 2026
Trendlines Group provided a corporate update detailing recent governance activities and portfolio company milestones that highlight its role as an incubator of emerging technologies. The company reported on its 2026 Annual General Meeting and Spec...
Trendlines’ Celleste Bio Debuts Milk Chocolate Made with Cell-Cultured Cocoa Butter
Apr 21, 2026
Trendlines Group’s portfolio company Celleste Bio has unveiled what it calls the world’s first milk chocolate bars made with real cocoa butter produced via cell suspension culture, marking a milestone in alternative cocoa sourcing. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.